Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gammagard Liquid for Infection Prophylaxis in Multiple Myeloma Patients Receiving Teclistamab
NCT06980480Phase 3Recruiting
- Sponsor
- Takeda
- Start
- Jan 2026
- Primary completion
- Sep 2028
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 17
01
Overview
A Phase 3 trial of intravenous immunoglobulin G in secondary immunodeficiency (SID), sponsored by Takeda. Started Jan 2026; status: recruiting.
02
Drugs
intravenous immunoglobulin G
03
Conditions
secondary immunodeficiency (SID)
Beyond the preview
Go deeper on NCT06980480.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06980480.